These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35250973)

  • 1. High PIRCHE Scores May Allow Risk Stratification of Borderline Rejection in Kidney Transplant Recipients.
    Lezoeva E; Nilsson J; Wüthrich R; Mueller TF; Schachtner T
    Front Immunol; 2022; 13():788818. PubMed ID: 35250973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIRCHE-II scores prove useful as a predictive biomarker among kidney transplant recipients with rejection: An analysis of indication and follow-up biopsies.
    Spitznagel T; Matter LS; Kaufmann YL; Nilsson J; von Moos S; Schachtner T
    Front Immunol; 2022; 13():949933. PubMed ID: 36059499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between PIRCHE-II scores and de novo allosensitization after reduction of immunosuppression during SARS-CoV-2 infection in kidney transplant recipients.
    Castrezana-Lopez K; Malchow R; Nilsson J; Kokkonen SM; Rho E; von Moos S; Mueller TF; Schachtner T
    Transpl Infect Dis; 2023 Apr; 25(2):e14052. PubMed ID: 36884207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulins do not prove beneficial to reduce alloimmunity among kidney transplant recipients with BKV-associated nephropathy.
    Naef B; Nilsson J; Wuethrich RP; Mueller TF; Schachtner T
    Transpl Int; 2021 Aug; 34(8):1481-1493. PubMed ID: 33872427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation.
    Senev A; Van Loon E; Lerut E; Coemans M; Callemeyn J; Daniëls L; Kerkhofs J; Koshy P; Kuypers D; Lamarthée B; Sprangers B; Tinel C; Van Craenenbroeck AH; Van Sandt V; Emonds MP; Naesens M
    Am J Kidney Dis; 2022 Dec; 80(6):718-729.e1. PubMed ID: 35690154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic risk stratification of pediatric heart transplant patients by combining HLAMatchmaker and PIRCHE-II.
    Mangiola M; Ellison MA; Marrari M; Bentlejewski C; Sadowski J; Zern D; Niemann M; Feingold B; Webber SA; Zeevi A;
    J Heart Lung Transplant; 2022 Jul; 41(7):952-960. PubMed ID: 35437211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of T and B Cell Epitopes to Predict the Risk of
    Sakamoto S; Iwasaki K; Tomosugi T; Niemann M; Spierings E; Miwa Y; Horimi K; Takeda A; Goto N; Narumi S; Watarai Y; Kobayashi T
    Front Immunol; 2020; 11():2000. PubMed ID: 32973806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring predicted indirectly recognizable HLA epitopes (PIRCHE-II) in liver transplant recipients on calcineurin inhibitor-free maintenance immunosuppression. A retrospective single center study.
    Meszaros M; Niemann M; Ursic-Bedoya J; Faure S; Meunier L; Rivière B; Costes-Martineau V; Thevenin C; Pageaux GP
    Transpl Immunol; 2020 Apr; 59():101272. PubMed ID: 32061667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic risk stratification of pediatric heart transplant patients by combining HLA-EMMA and PIRCHE-II.
    Ellison M; Mangiola M; Marrari M; Bentlejewski C; Sadowski J; Zern D; Kramer CSM; Heidt S; Niemann M; Xu Q; Dipchand AI; Mahle WT; Rossano JW; Canter CE; Singh TP; Zuckerman WA; Hsu DT; Feingold B; Webber SA; Zeevi A
    Front Immunol; 2023; 14():1110292. PubMed ID: 36999035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The number of donor HLA-derived T cell epitopes available for indirect antigen presentation determines the risk for vascular rejection after kidney transplantation.
    Betjes MGH; Peereboom ETM; Otten HG; Spierings E
    Front Immunol; 2022; 13():973968. PubMed ID: 36110856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship of distribution frequency of HLA antigen/antibody and PIRCHE score with DSA production and AMR occurrence].
    Zheng J; Kuang PD; Zhang Y; Zhao Q; He XL; Ding XM; Xue WJ
    Zhonghua Yi Xue Za Zhi; 2019 Mar; 99(12):901-906. PubMed ID: 30917438
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictive value of HLAMatchmaker and PIRCHE-II scores for de novo donor-specific antibody formation after adult and pediatric liver transplantation.
    Hamada S; Dumortier J; Thévenin C; Pageaux GP; Faure S; Guillaud O; Boillot O; Lachaux A; Luscalov DA; Dubois V; Meszaros M
    Transpl Immunol; 2020 Aug; 61():101306. PubMed ID: 32422222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mismatch Predicts T Cell-Mediated Rejection and De Novo Donor-Specific Antibody Formation After Living Donor Liver Transplantation.
    Ono K; Ide K; Tanaka Y; Ohira M; Tahara H; Tanimine N; Yamane H; Ohdan H
    Liver Transpl; 2021 Nov; 27(11):1592-1602. PubMed ID: 34310028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can PIRCHE-II Matching Outmatch Traditional HLA Matching?
    Unterrainer C; Döhler B; Niemann M; Lachmann N; Süsal C
    Front Immunol; 2021; 12():631246. PubMed ID: 33717167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection.
    Wiebe C; Rush DN; Gibson IW; Pochinco D; Birk PE; Goldberg A; Blydt-Hansen T; Karpinski M; Shaw J; Ho J; Nickerson PW
    Am J Transplant; 2020 Sep; 20(9):2499-2508. PubMed ID: 32185878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study.
    Lee DR; Kim BC; Kim JP; Kim IG; Jeon MY
    Transplant Proc; 2018 Dec; 50(10):3452-3459. PubMed ID: 30503524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The negative impact of T cell-mediated rejection on renal allograft survival in the modern era.
    Rampersad C; Balshaw R; Gibson IW; Ho J; Shaw J; Karpinski M; Goldberg A; Birk P; Rush DN; Nickerson PW; Wiebe C
    Am J Transplant; 2022 Mar; 22(3):761-771. PubMed ID: 34717048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and Clinical Significance of De Novo Donor-Specific Anti-HLA Antibodies after Kidney Transplantation.
    Jung HY; Kim SH; Seo MY; Cho SY; Yang Y; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
    J Korean Med Sci; 2018 Aug; 33(34):e217. PubMed ID: 30127706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIRCHE-II Is Related to Graft Failure after Kidney Transplantation.
    Geneugelijk K; Niemann M; Drylewicz J; van Zuilen AD; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Hack CE; van Reekum FE; Verhaar MC; Kamburova EG; Bots ML; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Vanderlocht J; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed A; Lardy JNM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; Spierings E
    Front Immunol; 2018; 9():321. PubMed ID: 29556227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 25-hydroxyvitamin D sufficiency is associated with lower de novo anti-HLA donor specific antibody and better kidney transplant outcomes.
    Bakis H; Bouthemy C; Corcuff JB; Lauro C; Guidicelli G; Cargou M; Guibet C; Taton B; Merville P; Couzi L; Moreau K; Visentin J
    HLA; 2024 Jan; 103(1):e15187. PubMed ID: 37604171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.